The warning comes after a report of a patient who experienced significant liver injury symptoms after about 40 days of use, according to a Sept. 12 news release from the agency.
An Astellas spokesperson told Becker’s, “Astellas remains dedicated to ensuring Veozah is accessible for appropriate patients who may benefit from a non-hormonal treatment option proven to reduce the frequency and severity of moderate to severe vasomotor symptoms (VMS) due to menopause.”
The FDA has updated the prescribing information for Veozah, advising more frequent liver blood testing during the first months of treatment. Healthcare providers are also instructed to perform regular liver function tests before and during treatment as well as educate patients about risks.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
